Showing results (21-30 of 41) with videos related to
Sort By:
Pageof 5
Frontiers in Endocrinology|January 11, 2021
Effects of Obesity and Thrombophilia on the Risk of Abortion in Women Undergoing In Vitro FertilizationMatteo Candeloro, Marcello Di Nisio, Adalisa Ponzano, et al.Reviews in Cardiovascular Medicine|July 30, 2024
Novel Pathophysiological, Diagnostic and Therapeutic Concepts in Acute and Recurrent PericarditisAldo Bonaventura, Georgia K Thomas, Michele Golino, et al.Cardiovascular Research|May 30, 2023
NLRP3 inflammasome and interleukin-1 contributions to COVID-19-associated coagulopathy and immunothrombosisNicola Potere, Evan Garrad, Yogendra Kanthi, et al.Thrombosis Research|April 30, 2023
Apixaban thromboprophylaxis in ambulatory patients with cancer and obesity: Insights from the AVERT trialNicola Potere, Marcello Di Nisio, Ettore Porreca, et al.Journal of Cardiovascular Pharmacology|February 13, 2019
The NLRP3 Inflammasome Inhibitor, OLT1177 (Dapansutrile), Reduces Infarct Size and Preserves Contractile Function After Ischemia Reperfusion Injury in the MouseStefano Toldo, Adolfo Gabriele Mauro, Zachary Cutter, et al.Ebiomedicine|October 9, 2022
Interleukin-1 and the NLRP3 inflammasome in COVID-19: Pathogenetic and therapeutic implicationsNicola Potere, Marco Giuseppe Del Buono, Roberto Caricchio, et al.Pharmacology & Therapeutics|February 1, 2026
Therapeutic management of inflammatory heart diseasesAldo Bonaventura, Marco Giuseppe Del Buono, Michele Golino, et al.Journal of Cardiovascular Pharmacology|November 14, 2018
An Orally Available NLRP3 Inflammasome Inhibitor Prevents Western Diet-Induced Cardiac Dysfunction in MiceSalvatore Carbone, Adolfo G Mauro, Andrea Prestamburgo, et al.Journal of the American Geriatrics Society|August 17, 2022
Frailty phenotype as a predictor of bleeding and mortality in ambulatory patients receiving direct oral anticoagulantsMatteo Candeloro, Marcello Di Nisio, Nicola Potere, et al.Journal of Cardiovascular Pharmacology|July 30, 2019
Alirocumab in Acute Myocardial Infarction: Results From the Virginia Commonwealth University Alirocumab Response Trial (VCU-AlirocRT)Cory R Trankle, George Wohlford, Leo F Buckley, et al.Pageof 5